[HTML] sciencedirect.com

[HTML][HTML] Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers

M Margoni, P Preziosa, P Tortorella, M Filippi… - …, 2022 - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
被引用次数：13 相关文章

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella… - …, 2022 - research.unipd.it
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

M Margoni, P Preziosa, P Tortorella… - …, 2022 - search.ebscohost.com
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

M Margoni, P Preziosa, P Tortorella… - … : the Journal of the …, 2022 - europepmc.org
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
[HTML] springer.com

[HTML][HTML] Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella, M Filippi… - …, 2022 - Springer
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella, M Filippi… - …, 2022 - search.proquest.com
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella… - … : the journal of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
[PDF] researchgate.net

[PDF][PDF] Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella, M Filippi… - 2022 - researchgate.net
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
[HTML] nih.gov

[HTML][HTML] Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella, M Filippi… - …, 2022 - ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
[HTML] neurotherapeuticsjournal.org

[HTML][HTML] Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

M Margoni, P Preziosa, P Tortorella… - …, 2022 - neurotherapeuticsjournal.org
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …